Multiple sclerosis classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 15: Line 15:
Patient with long term RRMS can switch to [[SPMS]], when the [[neurological]] [[symptoms]] progressively worsen between the attacks.<ref name=":0" />
Patient with long term RRMS can switch to [[SPMS]], when the [[neurological]] [[symptoms]] progressively worsen between the attacks.<ref name=":0" />
;'''Primary progressive:'''
;'''Primary progressive:'''
PPSM is
PPSM i
;  '''Progressive relapsing:'''
;  '''Progressive relapsing:'''
;  
;  

Revision as of 09:26, 21 January 2018

Multiple sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Alternative Therapies

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple sclerosis classification On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple sclerosis classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple sclerosis classification

CDC on Multiple sclerosis classification

Multiple sclerosis classification in the news

Blogs on Multiple sclerosis classification

Directions to Hospitals Treating Multiple sclerosis

Risk calculators and risk factors for Multiple sclerosis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Classification

Multiple sclerosis may be classified according to clinical course into four groups:[1]

Relapsing-remitting:

RRMS in defined by acute attacks of neurological dysfunction followed by full or partial recovery. Patient clinical symptoms are stable between the attacks.[1]

Secondary progressive:

Patient with long term RRMS can switch to SPMS, when the neurological symptoms progressively worsen between the attacks.[1]

Primary progressive:

PPSM i

Progressive relapsing:
These subtypes were defined In 1996 by the US National Multiple Sclerosis Society (NMSS).[1]

Nevertheless the earliest clinical presentation of relapsing-remitting MS (RRMS) is the clinically isolated syndrome (CIS). In CIS, there is a subacute attack suggestive of demyelination but the person does not fullfill the criteria for multiple sclerosis.[2] Several studies have shown that starting treatment with interferons during the initial attack can decrease the chance that a patient will develop MS.[3][4][5]

Special cases of the disease with non-standard behavior have also been described although many researchers believe they are different diseases. These cases are sometimes referred to as borderline forms of multiple sclerosis and are Neuromyelitis optica (NMO), Balo concentric sclerosis, Schilder's diffuse sclerosis and Marburg multiple sclerosis.[6]

References

  1. 1.0 1.1 1.2 1.3 Lublin FD; Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 Apr;46(4):907-11. PMID 8780061
  2. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (2005). "Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis". Lancet neurology. 4 (5): 281–8. doi:10.1016/S1474-4422(05)70071-5. PMID 15847841.
  3. Jacobs LD; Beck RW; Simon JH; Kinkel RP; Brownscheidle CM; Murray TJ; Simonian NA; Slasor PJ; Sandrock AW. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 September 28;343(13):898–904. PMID 11006365
  4. Comi G; Filippi M; Barkhof F; Durelli L; Edan G; Fernandez O; Hartung H; Seeldrayers P; Sorensen PS; Rovaris M; Martinelli V; Hommes OR.Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.Lancet 2001 May 19;357(9268):1576–82. PMID 11377645
  5. Kappos L, Freedman MS, Polman CH; et al. (2007). "Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study". Lancet. 370 (9585): 389–97. doi:10.1016/S0140-6736(07)61194-5. PMID 17679016.
  6. Borderline forms of MS, Fontaine, B., Federation de Neurologie, INSERM U546, Groupe Hospitalier, Faculte de Medecine Pitie-Salpetriere, Paris [1]

Template:WH Template:WS